Drug Study – Catopril

Capoten

Action:

Lowers blood pressure by specific inhibition of the angiotensin-converting enzyme (ACE). This interrupts conversion sequences initiated by renin that lead to formation of angiotensin II, a potent endogenous vasoconstrictor. ACE inhibition alters hemodynamics without compensatory reflex tachycardia or changes in cardiac output (except in patients with CHF). Peripheral vascular resistance is lowered by vasodilation. Inhibition of ACE also leads to decreased circulating aldosterone. Reduced circulating aldosterone is associated with a potassium-sparing effect. In heart failure, captopril administration is followed by a fall in CVP and pulmonary wedge pressure; hypotensive action appears to be unrelated to plasma renin levels.

Classifications:

cardiovascular agent; angiotensin-converting enzyme (ace) inhibitor; antihypertensive agent

Indication:

Hypertension; in conjunction with digitalis and diuretics in CHF, diabetic nephropathy.

Download

Advertisements:

Related posts:

1. Drug Study – Losartan Potassium Cozaar Action: Angiotensin II receptor (type AT1) antagonist acts as...
2. Drug Study – Trimethoprim-Sulfamethoxazole (TMP-SMZ) Bactrim, Co-Trimoxazole, Septra Action: Fixed combination of sulfamethoxazole (SMZ), an...
3. Drug Study – Clonidine Hydrochloride Catapres, Catapres-TTS, Dixaril , Duraclon Action: Centrally acting antiadrenergic derivative....
4. Drug Study – Phenobarbital Sodium Luminal Sodium Action: Long-acting barbiturate. Sedative and hypnotic effects of...
5. Drug Study – Diazepam Action: Psychotherapeutic agent related to chlordiazepoxide; reportedly superior in antianxiety...